CGP 50068

Drug Profile

CGP 50068

Alternative Names: CGP 39540; CGP 50068A

Latest Information Update: 15 Jul 1999

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Class Neuroprotectants; Nootropics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 15 Jul 1999 No-Development-Reported for Alzheimer's disease in Switzerland (Unknown route)
  • 18 Apr 1996 New profile
  • 18 Apr 1996 Phase-I clinical trials for Alzheimer's disease in Switzerland (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top